Contrasting effects of steroids and mizoribine on macrophage activation and glomerular lesions in rat Thy-1 mesangial proliferative glomerulonephritis

Yohei Ikezumi, Toshiaki Suzuki, Tamaki Karasawa, Hiroya Hasegawa, Hiroshi Kawachi, David J. Nikolic-Paterson, Makoto Uchiyama

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: Macrophages with a pro-inflammatory (M1) phenotype mediate renal injury in proliferative forms of glomerulonephritis, while alternatively activated (M2) macrophages are thought to be anti-inflammatory and promote repair. Glucocorticoids, the mainstay therapy for proliferative glomerulonephritis, can induce alternative macrophage activation in vitro, but it is unknown whether this occurs in vivo and if this is required for glucocorticoid responsiveness. In addition, clinical studies have suggested that the ability of mizoribine (MZR) to suppress steroid-resistant proliferative glomerulonephritis may operate via inhibiting pro-inflammatory macrophage activation. Methods: This study examined prednisolone (PSL) and/or MZR treatment of rat Thy-1 disease - a model in which macrophages promote mesangial proliferative glomerulonephritis. Results: PSL treatment of Thy-1 nephritis induced an M2-like macrophage phenotype, but failed to modify mesangial hypercellularity and actually exacerbated global glomerulosclerosis. In contrast, MZR treatment reduced hypercellularity and glomerulosclerosis and suppressing both M1 and M2 markers of macrphage activation, with a selective reduction in CD169+ macrophages. Combined PSL/MZR treatment suppressed glomerular lesions and prevented steroid induction of an M2-like macrophage phenotype. In vitro, MZR prevented steroid induction of an M2 macrophage phenotype. Conclusions: Glucocorticoid induced alternative macrophage activation failed to ameliorate rat mesangial proliferative glomerulonephritis, whereas MZR suppression of this disease model was attributed, in part, to inhibition of M1-like pro-inflammatory macrophage activation.

Original languageEnglish
Pages (from-to)273-282
Number of pages10
JournalAmerican Journal of Nephrology
Volume31
Issue number3
DOIs
Publication statusPublished - 01-03-2010
Externally publishedYes

Fingerprint

Macrophage Activation
Glomerulonephritis
Macrophages
Steroids
Prednisolone
Glucocorticoids
Phenotype
Nephritis
bredinin
Anti-Inflammatory Agents
Kidney
Wounds and Injuries

All Science Journal Classification (ASJC) codes

  • Nephrology

Cite this

Ikezumi, Yohei ; Suzuki, Toshiaki ; Karasawa, Tamaki ; Hasegawa, Hiroya ; Kawachi, Hiroshi ; Nikolic-Paterson, David J. ; Uchiyama, Makoto. / Contrasting effects of steroids and mizoribine on macrophage activation and glomerular lesions in rat Thy-1 mesangial proliferative glomerulonephritis. In: American Journal of Nephrology. 2010 ; Vol. 31, No. 3. pp. 273-282.
@article{df722c1ca25d4e918e7208f68d0dbeb7,
title = "Contrasting effects of steroids and mizoribine on macrophage activation and glomerular lesions in rat Thy-1 mesangial proliferative glomerulonephritis",
abstract = "Background: Macrophages with a pro-inflammatory (M1) phenotype mediate renal injury in proliferative forms of glomerulonephritis, while alternatively activated (M2) macrophages are thought to be anti-inflammatory and promote repair. Glucocorticoids, the mainstay therapy for proliferative glomerulonephritis, can induce alternative macrophage activation in vitro, but it is unknown whether this occurs in vivo and if this is required for glucocorticoid responsiveness. In addition, clinical studies have suggested that the ability of mizoribine (MZR) to suppress steroid-resistant proliferative glomerulonephritis may operate via inhibiting pro-inflammatory macrophage activation. Methods: This study examined prednisolone (PSL) and/or MZR treatment of rat Thy-1 disease - a model in which macrophages promote mesangial proliferative glomerulonephritis. Results: PSL treatment of Thy-1 nephritis induced an M2-like macrophage phenotype, but failed to modify mesangial hypercellularity and actually exacerbated global glomerulosclerosis. In contrast, MZR treatment reduced hypercellularity and glomerulosclerosis and suppressing both M1 and M2 markers of macrphage activation, with a selective reduction in CD169+ macrophages. Combined PSL/MZR treatment suppressed glomerular lesions and prevented steroid induction of an M2-like macrophage phenotype. In vitro, MZR prevented steroid induction of an M2 macrophage phenotype. Conclusions: Glucocorticoid induced alternative macrophage activation failed to ameliorate rat mesangial proliferative glomerulonephritis, whereas MZR suppression of this disease model was attributed, in part, to inhibition of M1-like pro-inflammatory macrophage activation.",
author = "Yohei Ikezumi and Toshiaki Suzuki and Tamaki Karasawa and Hiroya Hasegawa and Hiroshi Kawachi and Nikolic-Paterson, {David J.} and Makoto Uchiyama",
year = "2010",
month = "3",
day = "1",
doi = "10.1159/000279163",
language = "English",
volume = "31",
pages = "273--282",
journal = "American Journal of Nephrology",
issn = "0250-8095",
publisher = "S. Karger AG",
number = "3",

}

Contrasting effects of steroids and mizoribine on macrophage activation and glomerular lesions in rat Thy-1 mesangial proliferative glomerulonephritis. / Ikezumi, Yohei; Suzuki, Toshiaki; Karasawa, Tamaki; Hasegawa, Hiroya; Kawachi, Hiroshi; Nikolic-Paterson, David J.; Uchiyama, Makoto.

In: American Journal of Nephrology, Vol. 31, No. 3, 01.03.2010, p. 273-282.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Contrasting effects of steroids and mizoribine on macrophage activation and glomerular lesions in rat Thy-1 mesangial proliferative glomerulonephritis

AU - Ikezumi, Yohei

AU - Suzuki, Toshiaki

AU - Karasawa, Tamaki

AU - Hasegawa, Hiroya

AU - Kawachi, Hiroshi

AU - Nikolic-Paterson, David J.

AU - Uchiyama, Makoto

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Background: Macrophages with a pro-inflammatory (M1) phenotype mediate renal injury in proliferative forms of glomerulonephritis, while alternatively activated (M2) macrophages are thought to be anti-inflammatory and promote repair. Glucocorticoids, the mainstay therapy for proliferative glomerulonephritis, can induce alternative macrophage activation in vitro, but it is unknown whether this occurs in vivo and if this is required for glucocorticoid responsiveness. In addition, clinical studies have suggested that the ability of mizoribine (MZR) to suppress steroid-resistant proliferative glomerulonephritis may operate via inhibiting pro-inflammatory macrophage activation. Methods: This study examined prednisolone (PSL) and/or MZR treatment of rat Thy-1 disease - a model in which macrophages promote mesangial proliferative glomerulonephritis. Results: PSL treatment of Thy-1 nephritis induced an M2-like macrophage phenotype, but failed to modify mesangial hypercellularity and actually exacerbated global glomerulosclerosis. In contrast, MZR treatment reduced hypercellularity and glomerulosclerosis and suppressing both M1 and M2 markers of macrphage activation, with a selective reduction in CD169+ macrophages. Combined PSL/MZR treatment suppressed glomerular lesions and prevented steroid induction of an M2-like macrophage phenotype. In vitro, MZR prevented steroid induction of an M2 macrophage phenotype. Conclusions: Glucocorticoid induced alternative macrophage activation failed to ameliorate rat mesangial proliferative glomerulonephritis, whereas MZR suppression of this disease model was attributed, in part, to inhibition of M1-like pro-inflammatory macrophage activation.

AB - Background: Macrophages with a pro-inflammatory (M1) phenotype mediate renal injury in proliferative forms of glomerulonephritis, while alternatively activated (M2) macrophages are thought to be anti-inflammatory and promote repair. Glucocorticoids, the mainstay therapy for proliferative glomerulonephritis, can induce alternative macrophage activation in vitro, but it is unknown whether this occurs in vivo and if this is required for glucocorticoid responsiveness. In addition, clinical studies have suggested that the ability of mizoribine (MZR) to suppress steroid-resistant proliferative glomerulonephritis may operate via inhibiting pro-inflammatory macrophage activation. Methods: This study examined prednisolone (PSL) and/or MZR treatment of rat Thy-1 disease - a model in which macrophages promote mesangial proliferative glomerulonephritis. Results: PSL treatment of Thy-1 nephritis induced an M2-like macrophage phenotype, but failed to modify mesangial hypercellularity and actually exacerbated global glomerulosclerosis. In contrast, MZR treatment reduced hypercellularity and glomerulosclerosis and suppressing both M1 and M2 markers of macrphage activation, with a selective reduction in CD169+ macrophages. Combined PSL/MZR treatment suppressed glomerular lesions and prevented steroid induction of an M2-like macrophage phenotype. In vitro, MZR prevented steroid induction of an M2 macrophage phenotype. Conclusions: Glucocorticoid induced alternative macrophage activation failed to ameliorate rat mesangial proliferative glomerulonephritis, whereas MZR suppression of this disease model was attributed, in part, to inhibition of M1-like pro-inflammatory macrophage activation.

UR - http://www.scopus.com/inward/record.url?scp=75149192714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75149192714&partnerID=8YFLogxK

U2 - 10.1159/000279163

DO - 10.1159/000279163

M3 - Article

VL - 31

SP - 273

EP - 282

JO - American Journal of Nephrology

JF - American Journal of Nephrology

SN - 0250-8095

IS - 3

ER -